EastGate Acquisitions Presents An Introduction To Its Self-Emulsifying Platform Delivery System For Enhancing Bioavailability Of Biologically Active Compounds

SALT LAKE CITY and TORONTO, May 20, 2014/ EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company aiming to make use of innovations in drug delivery for the development of improved novel formulations and alternative dosage forms for existing biologically active molecules. An introduction and a description of the company s platform delivery and formulation technology is summarized below: An analysis of currently marketed drugs identified a substantial number of compounds with poor bioavailability. Low absorption rates and poor bioavailability of a drug can necessitate an increase in the amount of drugs that patients receive. What advantages would be associated with a highly absorbable delivery system? Increased bioavailability could improve patient compliance, decrease side-effects, reduce treatment costs and offer a better quality of life. EastGate Acquisitions technology platform provides an effective approach for increasing bioavailability and lowering t
http://bit.ly/1klSUk4